Intraosseous Tranexamic Acid for Reducing Blood Loss in Total Knee Arthroplasty
Key facts
- Where
- Kunming, ChinaSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 85 years old?
Source: NCT07853885, who can take part
Where in China
- The Second Affiliated Hospital of Kunming Medical UniversityKunming, ChinaContact: Ning LuNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- The Second Affiliated Hospital of Kunming Medical University
- Trial code
- NCT07853885
- Record updated
- 9 October 2026
- Original description
This prospective, single-center, randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy and safety of local intraosseous tranexamic acid administration for reducing perioperative blood loss in patients undergoing primary unilateral total knee arthroplasty (TKA). A total of 70 patients with primary knee osteoarthritis will be randomly assigned in a 1:1 ratio to either the tranexamic acid group or the placebo control group. Before skin incision, participants in the experimental group will receive local intraosseous tranexamic acid, while participants in the control group will receive an equal volume of normal saline using the same injection procedure. The primary outcome is total perioperative blood loss. Secondary outcomes include postoperative hemoglobin reduction, transfusion requirements, pain, knee swelling, range of motion, functional recovery, length of hospital stay, and postoperative complications. Participants will be followed for up to 3 months after surgery.Read full original descriptionShow less
Efficacy and Safety of Local Intraosseous Tranexamic Acid Injection for Reducing Perioperative Blood Loss in Total Knee Arthroplasty: A Randomized, Double-Blind, Controlled Trial
This prospective, single-center, randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy and safety of local intraosseous tranexamic acid administration for reducing perioperative blood loss in patients undergoing primary unilateral total knee arthroplasty (TKA). A total of 70 patients with primary knee osteoarthritis will be randomly assigned in a 1:1 ratio to either the tranexamic acid group or the placebo control group. Before skin incision, participants in the experimental group will receive local intraosseous tranexamic acid, while participants in the control group will receive an equal volume of normal saline using the same injection procedure. The primary outcome is total perioperative blood loss. Secondary outcomes include postoperative hemoglobin reduction, transfusion requirements, pain, knee swelling, range of motion, functional recovery, length of hospital stay, and postoperative complications. Participants will be followed for up to 3 months after surgery.
Inclusion: Age 50 to 85 years; Diagnosis of primary knee osteoarthritis; Scheduled to undergo primary unilateral total knee arthroplasty; American Society of Anesthesiologists (ASA) physical status classification I to III; Willing to participate in the study and able to provide written informed consent.
Exclusion: Known hypercoagulable state or current use of anticoagulant therapy, except for protocol-permitted perioperative anticoagulation; Active infection or previous surgery on the study knee; Known allergy or hypersensitivity to tranexamic acid; History of thromboembolic disease, including deep vein thrombosis or pulmonary embolism; Severe cardiac, hepatic, or renal dysfunction; History of vascular stent implantation or peripheral vascular disease; Abnormal coagulation function, including an international normalized ratio (INR) greater than 1.5; Pregnancy or breastfeeding.